AstraZeneca drug cocktail succeeds in late-stage study to treat COVID-19

"An early intervention with our antibody can give a significant reduction in progression to severe disease, with continued protection for more than six months," said Mene Pangalos, executive vice president, biopharmaceuticals R&D at AstraZeneca.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news